Low relaxation rate in a low-Z alloy of iron

The longest relaxation time and sharpest frequency content in ferromagnetic precession is determined by the intrinsic (Gilbert) relaxation rate \emph{$G$}. For many years, pure iron (Fe) has had the lowest known value of $G=\textrm{57 Mhz}$ for all pure ferromagnetic metals or binary alloys. We show that an epitaxial iron alloy with vanadium (V) possesses values of $G$ which are significantly reduced, to 35$\pm$5 Mhz at 27% V. The result can be understood as the role of spin-orbit coupling in generating relaxation, reduced through the atomic number $Z$.Comment: 14 pages, 4 figure

Pioneer lichen communities of the Teteriv River Basin (Ukraine)

The results of phytosociological studies of pioneer lichen communities of siliceous outcrops carried out in 2014–2016 in Teteriv River basin (Ukraine) are provided. The dataset of 302 relevés was analysed, 6 associations and 1 subassociation from 3 classes were distinguished as a result of the phytosociological survey in the Teteriv River basin. Four associations, i.e.: Aspicilietum contortae Kaiser ex Klement 1955, Cladonietum mitis Krieger 1937, Parmelietum conspersae Hilitzer 1925, Parmelietum somloensis Wirth 1995 and the alliance Aspicilion calcareae Albertson ex Roux 1978 are new for Ukraine, and one new association Aspicilio cinerei-Ramalinetum pollinariae Kapets et Khomyak, ass. nova is described here

Femtomolar detection of the heart failure biomarker NT-proBNP in artificial saliva using an immersible liquid-gated aptasensor with reduced graphene oxide

Measuring NT-proBNP biomarker is recommended for preliminary diagnostics of the heart failure. Recent studies suggest a possibility of early screening of biomarkers in saliva for non-invasive identification of cardiac diseases at the point-of-care. However, NT-proBNP concentrations in saliva can be thousand time lower than in blood plasma, going down to pg/mL level. To reach this level, we developed a label-free aptasensor based on a liquid-gated field effect transistor using a film of reduced graphene oxide monolayer (rGO-FET) with immobilized NT-proBNP specific aptamer. We found that, depending on ionic strength of tested solutions, there were different levels of correlation in responses of electrical parameters of the rGO-FET aptasensor, namely, the Dirac point shift and transconductance change. The correlation in response to NT-proBNP was high for 1.6 mM phosphate-buffered saline (PBS) and zero for 16 mM PBS in a wide range of analyte concentrations, varied from 1 fg/mL to 10 ng/mL. The effects of transconductance and Dirac point shift in PBS solutions of different concentrations are discussed. The biosensor exhibited a high sensitivity for both transconductance (2 uS/decade) and Dirac point shift (2.3 mV/decade) in diluted PBS with the linear range from 10 fg/mL to 1 pg/mL. The aptasensor performance has been also demonstrated in undiluted artificial saliva with the achieved limit of detection down to 41 fg/mL (~4.6 fM)

Prevalence of diabetes mellitus in patients with acromegaly

Early carbohydrate metabolism disorders (ECMDs) and diabetes mellitus (DM) are frequently associated with acromegaly. We aimed to assess the prevalence of ECMDs in patients with acromegaly and to compare the results with those in adults without acromegaly using two population-based epidemiologic surveys. We evaluated 97 patients with acromegaly in several phases of their disease (mean age, 56 years and estimated duration of acromegaly, 12.5 years). An oral glucose tolerance test was done in those not yet diagnosed with DM to reveal asymptomatic DM or ECMDs (impaired glucose tolerance+impaired fasting glucose). Comparisons were made between patients with acromegaly and participants from the general adult population (n=435) and an adult population with multiple type 2 diabetes risk factors (n=314), matched for gender, age and BMI. DM was diagnosed in 51 patients with acromegaly (52.5%) and 14.3% of the general population (P<0.001). The prevalence of ECMDs was also higher in patients with acromegaly than in the general population and in the high-risk group; only 22% of patients with acromegaly were normoglycaemic. The prevalence of newly diagnosed ECMDs or DM was 1.3-1.5 times higher in patients with acromegaly compared with the high-risk group. Patients with acromegaly having ECMDs or DM were older, more obese and had longer disease duration and higher IGF1 levels (Z-score). Logistic regression showed that the severity of glucose derangement was predicted by age, BMI and IGF1 levels. In patients with acromegaly, the prevalence of DM and ECMDs considerably exceeds that of the general population and of a high-risk group, and development of DM depends on age, BMI and IGF1 levels